Search
Q32 Bio Inc
QTTBAdd to Watchlist
15.140USD
-0.010-0.07%
Close 07-27 16:00（ET）Quotes delayed by 15 min
186.29MMarket Cap
5.43P/E TTM
More Details of Q32 Bio Inc Company
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Q32 Bio Inc Info
Ticker SymbolQTTB
Company nameQ32 Bio Inc
IPO dateMar 28, 2018
CEOMorrison (Jodie Pope)
Number of employees42
Security typeOrdinary Share
Fiscal year-endMar 28
Address830 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone17819990232
Websitehttps://www.q32bio.com/
Ticker SymbolQTTB
IPO dateMar 28, 2018
CEOMorrison (Jodie Pope)
Company Executives of Q32 Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
FAQs
Who are the top five shareholders of Q32 Bio Inc?
The top five shareholders of Q32 Bio Inc are: Dr. Shelia M. Violette, Ph.D.
How many institutions hold shares of Q32 Bio Inc (QTTB)?
As of 2026Q1, 189 institutions hold shares of Q32 Bio Inc, with a combined market value of approximately 9.99M, accounting for 65.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2048479.00.